SEC Form 4 · accession 0001387131-18-002844
NUTRA PHARMA CORP · NPHC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rik J Deitsch
Officer — President, CEO · Director · 10% Owner
Period of report
Apr 10, 2014
Accepted (ET)
Jun 26, 2018 · 4:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001119643
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Nutra Pharma Corp Common Stock | Apr 10, 2014 | P | 1,250,000 | $0.08 | A | 4,791,959 | D | |
| Nutra Pharma Corp Common Stock | Dec 11, 2014 | A | 506,900 | $0.24 | A | 5,298,859 | D | |
| Nutra Pharma Corp Common Stock | Jun 13, 2015 | A | 4,000,000 | $0.185 | A | 9,298,859 | D | |
| Nutra Pharma Corp Common Stock | Jun 28, 2016 | A | 4,000,000 | $0.0135 | A | 13,298,859 | D | |
| Nutra Pharma Corp Common Stock | Jul 5, 2016 | P | 15,000,000 | $0.0067 | A | 28,298,859 | D | |
| Nutra Pharma Corp Common Stock | Dec 19, 2016 | P | 15,000,000 | $0.005 | A | 43,298,859 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nutra Pharma Series A PreferredF1 | — | Oct 30, 2017 | A | 3,000,000 | A | — | — | Series A Preferred | 3,000,000 | 3,000,000 | D |
Explanation of responses
- F1Preferred shares have no right of conversion and are valued at $0.133 per share, which represents the actual cost paid. The Series A Preferred Stock will vote with the Corporation's common stock as a single class on all matters or consents for the Corporation's common stockholders. Each share of Series A Preferred Stock is entitled to one thousand votes per share.